v3.25.2
SEGMENTS
 3 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SEGMENTS

NOTE 11 SEGMENTS

 

The following table summarizes segment financial information by business segment for the three months ended and at June 30, 2025:

  

(in thousands) 

Beyond

Air

  

Beyond

Cancer

  

NeuroNos

   Total 
Cash, cash equivalents and marketable securities  $3,056   $1,777   $1,630   $6,463 
All other assets   21,241    398    12    21,651 
Total assets  $24,297   $2,175   $1,642   $28,114 
Total liabilities   (16,779)   (530)   (397)   (17,706)
Net assets  $7,518   $1,645   $1,245   $10,408 
Non-controlling interest  $-   $330   $151   $481 
Capital expenditures  $198   $-   $-   $198 
                     
Revenues  $1,760   $-   $-   $1,760 
Cost of revenues   (1,604)   -    -    (1,604)
Research and development   (2,234)   (529)   (323)   (3,086)
Selling, general, and administrative   (3,328)   (952)   (407)   (4,687)
Loss from operations   (5,406)   (1,481)   (730)   (7,617)
Interest and finance expense   (548)   -    -    (548)
Other non-operating income/(expense)   110    (25)   2    87 
Net loss before income taxes  $(5,844)  $(1,506)  $(728)  $(8,078)
Operating activities included in net loss:                    
Depreciation and amortization  $795   $10   $-   $805 
Stock-based compensation expense  $1,000   $512   $65   $1,577 
                     
Cash used in operations  $(3,755)  $(439)  $(332)  $(4,526)
Cash from investing   215    361    -    576 
Cash from financing   4,066    -    -    4,066 
Impact of exchange rates   148    31    (52)   127 
Net change for the period  $674   $(47)  $(384)  $243 

 

The following table summarizes segment financial information by business segment for the three months ended and at June 30, 2024:

 

(in thousands) 

Beyond

Air

  

Beyond

Cancer

  

NeuroNos

   Total 
Cash, cash equivalents and marketable securities  $13,158   $8,216   $-   $21,374 
All other assets   24,357    769    -    25,126 
Total assets  $37,515   $8,985   $-   $46,500 
Total liabilities   (27,722)   (1,078)   -    (28,801)
Net assets  $9,793   $7,907   $-   $17,699 
Non-controlling interest  $-   $1,570   $-   $1,570 
Capital expenditures  $2,650   $23   $-   $2,673 
                     
Revenues  $683   $-   $-   $683 
Cost of revenues   (1,016)   -    -    (1,016)
Research and development   (4,078)   (1,930)   -    (6,009)
Selling, general, and administrative   (4,878)   (2,361)   -    (7,239)
Loss from operations   (9,289)   (4,291)   -    (13,580)
Interest and finance expense   (964)   -    -    (964)
Other non-operating income/(expense)   1,467    22    -    1,489 
Net loss before income taxes  $(8,786)  $(4,269)  $-   $(13,055)
Operating activities included in net loss:                    
Depreciation and amortization  $719   $17   $-   $736 
Stock-based compensation expense  $1,950   $1,429   $-   $3,379 
                     
Cash used in operations  $(7,500)  $(2,680)  $-   $(10,180)
Cash used in investing   5,405    (2,290)   -    3,114 
Cash from financing   (264)   -    -    (264)
Impact of exchange rates   21    90    -    111 
Net change for the period  $(2,338)  $(4,880)  $-   $(7,218)